Imbruvica and Movicol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imbruvica (ibrutinib) and Movicol (polyethylene glycol 3350). Common drug interactions include hypotension among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Imbruvica and Movicol. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Movicol?

Movicol has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 14,249 Movicol users. Check the latest studies of Movicol.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

32 people who take Imbruvica and Movicol together, and have interactions are studied.

Imbruvica and Movicol drug interactions.

What are the common drug interactions of Imbruvica and Movicol, by gender? *:

female:

  1. Hypotension (abnormally low blood pressure)
  2. Abdominal pain
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Back pain
  6. Dry eye (lack of adequate tears)
  7. Eye pain
  8. Febrile neutropenia (fever with reduced white blood cells)
  9. Gamma-glutamyltransferase increased
  10. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Anaemia (lack of blood)
  3. Abscess intestinal (collections of pus-intestinal)
  4. Bronchial carcinoma (lung cancer)
  5. Tracheobronchitis (an inflammation or infection, which affects the trachea and bronchi of respiratory tract)
  6. Subdural haematoma (blood collects between the skull and the surface of the brain)
  7. Subdural haemorrhage (bleeding between the skull and the surface of the brain)
  8. Urinary tract infection
  9. Anuria (failure of the kidneys to produce urine)
  10. Death

What are the common drug interactions of Imbruvica and Movicol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Abdominal pain
  2. Alanine aminotransferase increased
  3. Aspartate aminotransferase increased
  4. Back pain
  5. Dry eye (lack of adequate tears)
  6. Eye pain
  7. Febrile neutropenia (fever with reduced white blood cells)
  8. Gamma-glutamyltransferase increased
  9. Hypotension (abnormally low blood pressure)
  10. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Encephalopathy (functioning of the brain is affected by some agent or condition)

50-59:

  1. Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
  2. Inflammation
  3. Muscular weakness (muscle weakness)
  4. Neurosarcoidosis (a condition of unknown cause featuring a collection of immune cells in various tissues, involving the central nervous system (brain and spinal cord))
  5. Sensory disturbance (sense disturbance)
  6. Urinary retention (the inability to completely or partially empty the bladder)

60+:

  1. Dyspnoea (difficult or laboured respiration)
  2. Anaemia (lack of blood)
  3. Pneumonia
  4. Lung carcinoma cell type unspecified recurrent (lung cancer reoccurrence)
  5. Staphylococcal infection (an infection with staphylococcus bacteria)
  6. Abscess intestinal (collections of pus-intestinal)
  7. Bronchial carcinoma (lung cancer)
  8. Tracheobronchitis (an inflammation or infection, which affects the trachea and bronchi of respiratory tract)
  9. Hepatocellular injury (liver injury)
  10. Urinary tract infection

What are the existing conditions these people have? *

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 14 people, 43.75%
  2. Pain: 10 people, 31.25%
  3. Burkitt Lymphoma (cancer of the lymphatic system): 6 people, 18.75%
  4. Nausea (feeling of having an urge to vomit): 6 people, 18.75%
  5. Abdominal Pain: 4 people, 12.50%
  6. Gastric Ulcer (stomach ulcer): 4 people, 12.50%
  7. Gout (uric acid crystals building up in the body): 4 people, 12.50%
  8. Haematopoietic Stem Cell Mobilisation: 4 people, 12.50%
  9. Herpes Virus Infection: 4 people, 12.50%
  10. Depression: 4 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and Movicol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Imbruvica and Movicol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Movicol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Imbruvica and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Movicol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib and polyethylene glycol 3350 (the active ingredients of Imbruvica and Movicol, respectively), and Imbruvica and Movicol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: